Diligence memo · auto-generated · as of July 2, 2026
Aarvik Therapeutics, Inc.
Aarvik Therapeutics, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Aarvik Therapeutics, Inc. operates in Pharmaceuticals, based in Hayward.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aarvik Therapeutics, Inc. has raised $9.5M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $8.3M on 2021-08-18.
Most recent recorded round closed around 2024-11-04.
Valuation (modeled)modeled
Provath models Aarvik Therapeutics, Inc. at approximately $5.1M (range $1.3M–$10M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.16× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 39 months.
Last raise 20 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round was 7.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 53% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 10% of those peers.
Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.